Ian M. Catlett

机构：Bristol-Myers Squibb (United States), Incyte (United States) · ORCID：0000-0001-6220-2626

发表论文 58 篇 · 总被引 2088 次 · h-index 19

代表论文

• Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial (2022 · Arthritis & Rheumatology · 被引 264)
• First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2 (2022 · Clinical and Translational Science · 被引 61)
• Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study (2023 · The Lancet Rheumatology · 被引 22)
• Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses (2024 · Arthritis & Rheumatology · 被引 19)
• Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways (2024 · Frontiers in Immunology · 被引 8)
• Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial (2024 · Dermatology and Therapy · 被引 6)